|Security||AYTU / Aytu BioScience, Inc. (054754106)|
|Institutional Shares||709,313 - 39.38%|
|Common Shares Outstanding||1,801,411 shares (as of 2018-06-30)|
|Institutional Value||$ 186,000 USD|
Institutional Stock Ownership and Shareholders
Aytu BioScience, Inc. (NASDAQ:AYTU) has 2 institutional investors and shareholders that have
filed 13D/G or 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 709,313 shares.
Largest shareholders include
Sabby Management, LLC, and Barclays Plc.
Aytu BioScience, Inc. (NASDAQ:AYTU) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.
|Sabby Management, LLC||709,312||186|
|MCF Advisors LLC||357,142||0||-100.00||227||0||-100.00|
Related News Stories
New Age Beverages stock was on the rise today following news that it is getting a new CFO. (69-5)
DENVER, CO / ACCESSWIRE / October 12, 2018 / NEW AGE BEVERAGES CORPORATION (NASDAQ: NBEV), the Colorado-based organic, natural and healthy functional beverage company focused on becoming the world's leading healthy beverage company, today announced the appointment of Gregory A. Gould as its new Chief Financial and Administrative Officer. (69-1)
U.S. Patent Number 10,088,466 is Company's First United States Patent Covering MiOXSYS for Male Infertility Assessment (48-8)
ENGLEWOOD, CO / ACCESSWIRE / October 10, 2018 / Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, today announced the closing of an underwritten public offering on October 9, 2018, with total gross proceeds of $15.2 million which includes the full exercise of the underwriters' over-allotment option to purchase additional shares and warrants, before deducting underwriting discounts, commissions and other offering expenses payable by the Company. (48-0)
Associated Press (AP) recently analyzed and published data regarding brand-name prescription drug prices. This was largely in response to President Donald Trump’s promises during the presidential campaign and in a May policy announcement that he would drive down drug prices. In fact, at the end of May, Trump promised pharma companies would be announcing “massive” voluntary drug prices within two weeks. (49-0)
as of ET